Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) EBITDA
Johnson & Johnson's EBITDA for fiscal 2025 was $42.1B, up 61.3% from $26.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $34.9B. Over the past ten years it has ranged from $23.6B (fiscal 2015) to $42.1B (fiscal 2025) — the current reading is the highest in ten years. Johnson & Johnson ranks 2nd of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $42.1B | 61.26% |
| FY2024 | $26.1B | 6.23% |
| FY2023 | $24.6B | (9.28%) |
| FY2022 | $27.1B | 1.09% |
| FY2021 | $26.8B | 11.50% |
| FY2020 | $24.0B | (3.89%) |
| FY2019 | $25.0B | (5.77%) |
| FY2018 | $26.5B | 7.75% |
| FY2017 | $24.6B | (0.07%) |
| FY2016 | $24.7B | 4.36% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $9.2B | 8.37% |
| Mar 2026 | $8.5B | 14.36% |
| Dec 2025 | $7.4B | (23.75%) |
| Sep 2025 | $9.7B | 8.22% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LLY Eli Lilly and Company compare | $35.7B |
| JNJ Johnson & Johnson | $34.9B |
| ABBV AbbVie Inc. compare | $25.6B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement